OR WAIT null SECS
With estimates suggesting obstructive hypertrophic cardiomyopathy (oHCM) impacts 1-in-500 patients in the US, the advent of safe and efficacious therapies stands to have immediate and substantial impacts on disease management, quality of life for patients, and the societal burden of the most genetic cardiovascular condition. Because of this, news of US Food and Drug Administration’s approval of mavacamten (Camzyos) on April 28 was welcomed by the cardiology community as a historic advance for the field.
A first-in-class allosteric and reversible inhibitor selective for cardiac myosin approved based on the results of the EXPLORER-HCM trial, mavacamten was approved for the treatment of adults with symptomatic NYHA class 2-3 obstructive HCM after their phase 3 data indicated use was with improved exercise capacity, LVOT obstruction, NYHA functional class, and health status patients with oHCM.
In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, of Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, of Brigham and Women’s Hospital, are joined by special guest Anjali Owens, MD, of Penn Medicine. An assistant professor of medicine in the Division of Cardiology and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens is a leading researcher in oHCM with real-world clinical experience treating the disease, Owens takes our hosts on a deep dive into the disease state from her perspective.
All episodes of Don’t Miss a Beat are available in an audio-only format on Spotify and Apple Podcasts.